01 May 2004
Duration of Raynaud’s phenomenon is negatively correlated with serum levels of interleukin 10 (IL-10), soluble receptor of interleukin 2 (sIL2R), and sFas in systemic sclerosis patients
Bożena Dziankowska-Bartkowiak, Anna Zalewska, Anna Sysa-JędrzejowskaMed Sci Monit 2004; 10(5): CR202-208 :: ID: 11662
Abstract
Background:Dysfunction of blood vessels and endothelial cells is regarded as a primary triggering factor of the development of autoimmunological processes in systemic sclerosis (scleroderma, SSc). Literature data suggest that the duration of Raynaud’s phenomenon may correlate with disease severity.Material/Methods: The study comprised 34 patients with SSc, 19 with limited SSc (lSSc) and 15 with diffuse SSc (dSSc). The duration of Raynaud’s phenomenon (before skin fibrosis development) was correlated with the serum levels of selected markers, measured by ELISA, reflecting disturbances in autoimmunological processes, angiogenesis, apoptosis, and fibrosis.Results: A shorter duration of Raynaud’s phenomenon was shown to correlate with higher serum levels of interleukin-10 (IL-10) in the whole SSc group and of aminoterminal propeptide of collagen III (PIIINP) in the lSSc subgroup (p<0.05). It also correlated with higher serum levels of soluble interleukin 2 receptor (sIL2R) and the soluble protein sFas in the whole SSc group and the lSSc subgroup (p<0.05).
Conclusions: The results obtained confirm the importance of vasomotor disturbance duration in triggering fibrosis in the course of systemic sclerosis.
Keywords: Antigens, CD95 - blood, Cell Division, Enzyme-Linked Immunosorbent Assay, Fibrosis, Interleukin-10 - blood, Interleukin-10 - metabolism, Interleukin-2 - metabolism, Raynaud Disease - pathology, Receptors, Interleukin-2 - blood, Scleroderma, Systemic - blood, Time Factors, Antigens, CD95 - blood, Cell Division, Enzyme-Linked Immunosorbent Assay, Fibrosis, Interleukin-10 - metabolism, Interleukin-2 - metabolism, Raynaud Disease - pathology, Receptors, Interleukin-2 - blood, Scleroderma, Systemic - blood, Time Factors
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952